肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Blood杂志发表中和GM-CSF，解决CAR-T诱导神经毒性的潜力

2019-05-18 不详 MedSci原创

细胞疗法GM-CSFCAR-T神经毒性
关注

大多数接受CAR-T细胞疗法治疗的患者都是住院患者，有时需要入住重症监护病房（ICU）来管理神经毒性和细胞因子风暴等副作用。亟需改善CAR-T安全性而不会对疗效产生负面影响的策略，使CAR-T不仅可以在复发/难治性患者中使用，还可以用于早期治疗。

大多数接受CAR-T细胞疗法治疗的患者都是住院患者，有时需要入住重症监护病房（ICU）来管理神经毒性和细胞因子风暴等副作用。亟需改善CAR-T安全性而不会对疗效产生负面影响的策略，使CAR-T不仅可以在复发/难治性患者中使用，还可以用于早期治疗。

Humanigen宣布血液学顶尖杂志Blood发表了一篇题为"CAR-T细胞神经毒性：希望正在升起"的文章。该文章重点介绍了CAR-T细胞疗法神经毒性和细胞因子风暴的病理生理学，并确定了中和GM-CSF作为一种策略，有可能同时改善CAR-T的安全性和有效性，因为它具有双重机制。

"GM-CSF是炎性细胞因子级联中的关键上游触发因子，导致神经毒性和细胞因子风暴，并且还直接作用于骨髓谱系细胞，以促进髓源性抑制细胞（MDSC）和肿瘤相关巨噬细胞（TAM）的扩增和运输，已被证明可抑制T细胞增殖和效应功能。

"中和GM-CSF可能是下一代新策略，用于提高CAR-T疗法的疗效、安全性和成本效益，"Humanigen首席执行官Cameron Durrant博士说。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1668857, encodeId=6149166885ead, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Dec 23 07:33:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781301, encodeId=867a1e81301a7, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Aug 11 06:33:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484111, encodeId=f6cb148411179, content=<a href='/topic/show?id=81c2e4343a9' target=_blank style='color:#2F92EE;'>#神经毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74343, encryptionId=81c2e4343a9, topicName=神经毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42127951174, createdName=12498cf9m37(暂无昵称), createdTime=Mon May 20 07:33:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366448, encodeId=89fa36644870, content=向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬！, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun May 19 15:02:26 CST 2019, time=2019-05-19, status=1, ipAttribution=)]
    2019-12-23 kcb078

    #CSF#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1668857, encodeId=6149166885ead, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Dec 23 07:33:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781301, encodeId=867a1e81301a7, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Aug 11 06:33:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484111, encodeId=f6cb148411179, content=<a href='/topic/show?id=81c2e4343a9' target=_blank style='color:#2F92EE;'>#神经毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74343, encryptionId=81c2e4343a9, topicName=神经毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42127951174, createdName=12498cf9m37(暂无昵称), createdTime=Mon May 20 07:33:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366448, encodeId=89fa36644870, content=向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬！, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun May 19 15:02:26 CST 2019, time=2019-05-19, status=1, ipAttribution=)]
    2019-08-11 仁者大医

    #CAR-#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1668857, encodeId=6149166885ead, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Dec 23 07:33:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781301, encodeId=867a1e81301a7, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Aug 11 06:33:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484111, encodeId=f6cb148411179, content=<a href='/topic/show?id=81c2e4343a9' target=_blank style='color:#2F92EE;'>#神经毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74343, encryptionId=81c2e4343a9, topicName=神经毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42127951174, createdName=12498cf9m37(暂无昵称), createdTime=Mon May 20 07:33:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366448, encodeId=89fa36644870, content=向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬！, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun May 19 15:02:26 CST 2019, time=2019-05-19, status=1, ipAttribution=)]
    2019-05-20 12498cf9m37(暂无昵称)

    #神经毒性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1668857, encodeId=6149166885ead, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Dec 23 07:33:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781301, encodeId=867a1e81301a7, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Aug 11 06:33:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484111, encodeId=f6cb148411179, content=<a href='/topic/show?id=81c2e4343a9' target=_blank style='color:#2F92EE;'>#神经毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74343, encryptionId=81c2e4343a9, topicName=神经毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42127951174, createdName=12498cf9m37(暂无昵称), createdTime=Mon May 20 07:33:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366448, encodeId=89fa36644870, content=向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬！, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun May 19 15:02:26 CST 2019, time=2019-05-19, status=1, ipAttribution=)]
    2019-05-19 坚强007

    向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬！

    0

相关资讯

CAR-T细胞疗法公司Autolus计划后续融资1亿美元

最近纳斯达克上市的细胞治疗公司Autolus开始了公司的后续融资，期望筹集1亿美元。在去年首次公开募股 1亿美元之后，Autolus在后续融资之前将持有超过2亿美元的资金。

美国ASGCT ：Cell Medica公布其细胞疗法CAR-NKT的临床前数据

美国基因与细胞治疗学会年会（ASGCT），下一代细胞免疫治疗领导者Cell Medica宣布，其自然杀伤T细胞（CAR-NKT）疗法治疗复发/难治性（R / R）表达CD19的B-细胞恶性肿瘤的最新临床前数据。

MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药

MaxCyte公司宣布在美国开始MCY-M11的I期临床试验第二批患者的给药。MCY-M11是间皮素靶向的嵌合抗原受体（CAR）疗法，正在15名复发/难治性卵巢癌和腹膜间皮瘤患者中进行剂量递增试验，以评估MCY-M11的安全性和耐受性。

FDA批准NKMax America的NK细胞疗法SNK01用于难治性癌症患者的1期临床试验

NKMax America是一家生物技术公司，开发自然杀手（NK）细胞疗法，利用人体免疫系统发挥抗肿瘤作用，今天宣布美国食品和药物管理局FDA已接受SNK01的研究性新药（IND）申请。SNK01是一种自体NK细胞过继免疫治疗候选药物，申请用于治疗病理证实的常规治疗难以治愈的癌症患者。

Precision Biosciences为开发同种异体CAR-T细胞疗法筹集1亿美元资金

Precision Biosciences计划募集1亿美元，进一步开发同种异体的CAR-T细胞疗法候选药物PBCAR0191。这部分资金将推进候选药物进入1/2临床研究，以评估其在急性淋巴细胞白血病和非霍奇金淋巴瘤（NHL）中的药效。

同种异体CAR-T细胞疗法开发公司Cellectis同时在巴黎和美国建立大型厂房

Cellectis是一家开发同种异体CAR-T疗法的生物技术公司。目前该公司正在巴黎建造一个占地14000平方英尺的工厂，用于生产临床用品，同时也将在美国建造一个相当于巴黎工厂六倍规模的新厂房，以实现CAR-T的商业化生产。